• Explore /
  • Poster
  • / Combination of PDL-1 and PARP inhibition in an unselected population with metastatic castrate-resistant prostate cancer (mCRPC).

Combination of PDL-1 and PARP inhibition in an unselected population with metastatic castrate-resistant prostate cancer (mCRPC).

Abstract Poster

Authors

null

Fatima Karzai

National Cancer Institute at the National Institutes of Health, Bethesda, MD

Fatima Karzai , Ravi Amrit Madan , Helen Owens , Amy Hankin , Anna Couvillon , Lisa M Cordes , Farhad Fakhrejahani , Nicole D. Houston , Jane B. Trepel , Clara Chen , Daniel C. Edelman , Paul S. Meltzer , Seth M. Steinberg , James L. Gulley , William L. Dahut , Jung-min Lee

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary (Prostate) Cancer

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer - Advanced Disease

Clinical Trial Registration Number

NCT02484404

Citation

J Clin Oncol 35, 2017 (suppl; abstr 5026)

DOI

10.1200/JCO.2017.35.15_suppl.5026

Abstract #

5026

Poster Bd #

100

Abstract Disclosures

Similar Posters

First Author: Fatima Karzai

First Author: Maral DerSarkissian

First Author: Jamal Alamiri

Poster

2020 Genitourinary Cancers Symposium

Treatment response comparisons between <em>ATM</em> and <em>BRCA2</em> germline carriers for mCRPC.

Treatment response comparisons between ATM and BRCA2 germline carriers for mCRPC.

First Author: Alexandra Sokolova